According to a research report published earlier today, Wedbush has increased CIGNA's CI PT from $52 to $53.
In the report, CIGNA commented, “We are increasing our price target to $53 from $52 as investor concern turns to positive sentiment with court hearings over. We are decreasing our 2012E to $5.57 as March Medicare Advantage enrollment data from CMS was 40K, or 10%, and Part D 186K, or 15% below our estimate, which lowers our full-year estimates by $0.04 and $0.02, respectively. We also modestly increase SG&A estimates related to HealthSpring integration and modest deleveraging from changes in membership.”
Wedbush maintains its Neutral rating on CIGNA, which is currently trading at $47.77.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in